LYPD3 and breast carcinoma: Furthermore, the same research group showed that AGR2 and AGR3 were both co-expressed in estrogen receptor (EsR)-positive breast cancer and can physically interact with LY6/PLAUR Domain Containing 3 (LYPD3 /C4.4a) and extracellular alpha-dystroglycan (DAG-1) [109].